Norges Bank’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $996K | Buy |
+111,152
| New | +$996K | ﹤0.01% | 1545 |
|
|
2025
Q1 | – | Sell |
-524,804
| Closed | -$3.95M | – | 198 |
|
|
2024
Q4 | $3.95M | Buy |
+524,804
| New | +$3.95M | ﹤0.01% | 1552 |
|
|
2024
Q3 | – | Sell |
-651,635
| Closed | -$4.03M | – | 201 |
|
|
2024
Q2 | $4.03M | Sell |
651,635
-354,394
| -35% | -$2.19M | ﹤0.01% | 1602 |
|
|
2024
Q1 | $5.11M | Sell |
1,006,029
-1,210,583
| -55% | -$6.15M | ﹤0.01% | 1613 |
|
|
2023
Q4 | $13.3M | Buy |
2,216,612
+1,370,000
| +162% | +$8.21M | ﹤0.01% | 1397 |
|
|
2023
Q3 | $5.99M | Hold |
846,612
| – | – | ﹤0.01% | 1642 |
|
|
2023
Q2 | $5.96M | Sell |
846,612
-38,251
| -4% | -$269K | ﹤0.01% | 1673 |
|
|
2023
Q1 | $7.38M | Sell |
884,863
-267,253
| -23% | -$2.23M | ﹤0.01% | 1667 |
|
|
2022
Q4 | $13.2M | Buy |
1,152,116
+79,000
| +7% | +$907K | ﹤0.01% | 1461 |
|
|
2022
Q3 | $13.5M | Sell |
1,073,116
-912,249
| -46% | -$11.5M | ﹤0.01% | 1414 |
|
|
2022
Q2 | $21M | Buy |
1,985,365
+1,189,837
| +150% | +$12.6M | 0.01% | 1213 |
|
|
2022
Q1 | $12.9M | Buy |
795,528
+77,854
| +11% | +$1.27M | ﹤0.01% | 1607 |
|
|
2021
Q4 | $9.94M | Sell |
717,674
-79,000
| -10% | -$1.09M | ﹤0.01% | 1760 |
|
|
2021
Q3 | $11.4M | Buy |
796,674
+625,323
| +365% | +$8.99M | ﹤0.01% | 1722 |
|
|
2021
Q2 | $2.71M | Hold |
171,351
| – | – | ﹤0.01% | 1978 |
|
|
2021
Q1 | $1.74M | Sell |
171,351
-179,409
| -51% | -$1.82M | ﹤0.01% | 2005 |
|
|
2020
Q4 | $2.61M | Sell |
350,760
-681,333
| -66% | -$5.08M | ﹤0.01% | 1928 |
|
|
2020
Q3 | $3.55M | Buy |
1,032,093
+488,600
| +90% | +$1.68M | ﹤0.01% | 1913 |
|
|
2020
Q2 | $2.59M | Buy |
+543,493
| New | +$2.59M | ﹤0.01% | 1938 |
|